Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Maridebart Cafraglutide

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Amgen · Phase 3 · Recruiting · Enrollment 950

NCT07684144

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Maridebart Cafraglutide Low Dose Q4Wn/rn/rn/rn/r
Maridebart Cafraglutide Medium Dose Q4Wn/rn/rn/rn/r
Maridebart Cafraglutide Medium dose Q8Wn/rn/rn/rn/r
Placebo Q4W (Received Medium Dose Maridebart Cafraglutide in Parent Trial)n/rn/rn/rn/r
Maridebart Cafraglutide High Dose Q4Wn/rn/rn/rn/r
Maridebart Cafraglutide High Dose Q8Wn/rn/rn/rn/r
Placebo Q4W (Received High Dose Maridebart Cafraglutide in Parent Trial)n/rn/rn/rn/r
Maridebart Cafraglutide High Dose Q4W (Received Placebo in the Parent Trial)n/rn/rn/rn/r
Maridebart Cafraglutide Low Dose Q4W(Received Very Low Dose Maridebart Cafraglutide in Parent Trial)n/rn/rn/rn/r

Not shown

  • Maridebart Cafraglutide Low Dose Q4W: endpoint not reported
  • Maridebart Cafraglutide Medium Dose Q4W: endpoint not reported
  • Maridebart Cafraglutide Medium dose Q8W: endpoint not reported
  • Placebo Q4W (Received Medium Dose Maridebart Cafraglutide in Parent Trial): endpoint not reported
  • Maridebart Cafraglutide High Dose Q4W: endpoint not reported
  • Maridebart Cafraglutide High Dose Q8W: endpoint not reported
  • Placebo Q4W (Received High Dose Maridebart Cafraglutide in Parent Trial): endpoint not reported
  • Maridebart Cafraglutide High Dose Q4W (Received Placebo in the Parent Trial): endpoint not reported
  • Maridebart Cafraglutide Low Dose Q4W(Received Very Low Dose Maridebart Cafraglutide in Parent Trial): endpoint not reported